BLACK DIAMOND THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 127.61 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 41.76K shares, a 91.76% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 85.85K shares, a 69.49% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 73.63K shares, a 36.57% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 862.12K shares, a 55.22% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.93M shares, a 16.96% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.65M shares, a 13.25% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.45M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 41.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 127.61K shares 10-Q · filed 2026-08-05 | 127.61K shares derived: sum of 3 quarters · filed 2026-08-05 | 201.24K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 85.85K shares 10-Q · filed 2026-05-07 | 85.85K shares derived: sum of 2 quarters · filed 2026-05-07 | 159.48K shares derived: sum of 3 quarters · filed 2026-05-07 | 666.58K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 73.63K shares derived: sum of 2 quarters · filed 2026-03-16 | 580.73K shares derived: sum of 3 quarters · filed 2026-03-16 | 862.12K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 73.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 580.73K shares derived: sum of 2 quarters · filed 2025-11-06 | 862.12K shares 10-Q · filed 2025-11-06 | 2.56M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 507.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 788.49K shares 10-Q · filed 2025-08-07 | 2.48M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.60M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 281.40K shares 10-Q · filed 2025-05-12 | 1.97M shares derived: sum of 2 quarters · filed 2025-05-12 | 2.09M shares derived: sum of 3 quarters · filed 2025-05-12 | 2.19M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 1.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 1.81M shares derived: sum of 2 quarters · filed 2025-03-06 | 1.91M shares derived: sum of 3 quarters · filed 2025-03-06 | 1.93M shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 116.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 215.40K shares derived: sum of 2 quarters · filed 2024-11-05 | 231.90K shares 10-Q · filed 2024-11-05 | 609.02K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 99.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 115.82K shares 10-Q · filed 2024-08-06 | 492.95K shares derived: sum of 3 quarters · filed 2024-08-06 | 1.41M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 16.50K shares 10-Q · filed 2024-05-09 | 393.62K shares derived: sum of 2 quarters · filed 2024-05-09 | 1.31M shares derived: sum of 3 quarters · filed 2024-05-09 | 1.42M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 377.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 1.30M shares derived: sum of 2 quarters · filed 2024-03-12 | 1.41M shares derived: sum of 3 quarters · filed 2024-03-12 | 1.65M shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 918.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 1.03M shares derived: sum of 2 quarters · filed 2023-11-06 | 1.27M shares 10-Q · filed 2023-11-06 | |
| 2023-06-30 | 110.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 350.42K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 240.24K shares 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 1.45M shares 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |